Skip to main content
Fig. 2 | Molecular Medicine

Fig. 2

From: The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors

Fig. 2

ERBB4 and TP53 co-mutation predict an improved prognosis of NSCLC with ICIs treatment. A The relationship between ERBB4 and TP53 co-mutation and PFS of NSCLC patients treated by ICIs; B The relationship between ERBB4 and TP53 co-mutation and OS of NSCLC patients treated by ICIs; C The mutation status of ERBB4 and TP53 is associated with the durable clinical benefit (DCB) in cBioPortal for Cancer Genomics; D The mutation status of ERBB4 and TP53 is associated with the PD-L1 expression in cBioPortal for Cancer Genomics; E The mutation status of ERBB4 and TP53 is associated with the tumor mutational burden (TMB) level in cohort [MSKCC, J Clin Oncol 2018] from cBioPortal for Cancer Genomics; F The mutation status of ERBB4 and TP53 is associated with the TMB level in cohort [TMB and Immunotherapy (MSKCC, Nat Genet 2019)] from cBioPortal for Cancer Genomics; G The mutation status of ERBB4 and TP53 is associated with the TMB level in TCGA-LUAD cohort; H The mutation status of ERBB4 and TP53 is associated with the TMB level in TCGA-LUSC cohort

Back to article page